ALN-GO1: Interim Phase I/II data

Interim data from 32 healthy volunteers in Part A of a single-blind, placebo-controlled, dose-escalation, U.K. Phase I/II trial showed that single doses of 0.3, 1, 3 and 6 mg/kg subcutaneous ALN-GO1 w...